Clinical Trials Sponsored by Pronova BioPharma

Total 1515 results

Theravance Biopharma

Completed

A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)

Opioid Induced Constipation

United States
Theravance Biopharma

Completed

Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects

Symptomatic Neurogenic Orthostatic Hypertension | nOH

United States
Theravance Biopharma

Completed

Multiple Ascending Dose Study of TD-1439 in Healthy Adult and Elderly Subjects

Healthy Adults, Elderly Subjects

United States
Theravance Biopharma

Completed

Single Ascending Dose Study of TD-1439 in Healthy Subjects

Healthy Subjects

United States
Theravance Biopharma

Completed

SAD and MAD Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of TD-1473 in Healthy Subjects

Healthy

United States
Theravance Biopharma

Completed

TD-1607 SAD Study in Healthy Subjects

Serious Infections Due to Known or Suspected Gram-positive Pathogens

United States
Theravance Biopharma

Completed

TD-9855 Mass Balance Study

Fibromyalgia | ADHD

United States
Theravance Biopharma

Completed

Drug-Drug Interaction (DDI) Study for TD-9855

Drug Drug Interaction (DDI)

United States
Theravance Biopharma

Completed

Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study

Inflammatory Bowel Disease

United States
Theravance Biopharma

Completed

TD-6450 SAD and MAD in Healthy Subjects

Hepatitis C

United States
Mereo BioPharma

Completed

Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United States, Bulgaria, Czechia, Germany, Hungary, Italy, Latvia, Poland, Romania, Russian Federation
CTI BioPharma

Withdrawn

Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

Lymphoma | Leukemia

United States
CTI BioPharma

Terminated

Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Lung Cancer

United States
CTI BioPharma

Terminated

Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer

Lung Cancer

United States
CTI BioPharma

Completed

BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)

Lymphoma, Non-Hodgkin

United States, United Kingdom, France, Italy, India, Germany, Hungary, Argentina, Uruguay, Russian Federation, Bulgaria, Costa Rica, Ecuador, Estonia, Mexico, Panama, Peru, Poland, Romania, Ukraine
CTI BioPharma

Withdrawn

Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer

Lymphoma | Solid Tumor (Excluding CNS)

United States
DS Biopharma

Completed

Efficacy and Steroid Sparing Potential Study of DGLA Cream in Patients With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

Germany
Espero Biopharma

Unknown

Tecarfarin Anti-Coagulation Trial (TACT) (TACT)

Thrombosis | Thromboembolism
Theravance Biopharma

Terminated

A Phase 1, Multiple Intravenous Dose Study to Examine Safety, Tolerability, and PK of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects

Gastrointestinal Motility Disorder

United States
Mereo BioPharma

Completed

The Effect of Azithromycin on BCT197 Exposure in Healthy Male Volunteers

Interaction

United Kingdom
Recepta Biopharma

Completed

In Vitro Functional Modulation of Monocyte-derived Dendritic Cells of Patients With Cancer by Peptides

Metastatic Cancer

Brazil
CTI BioPharma

Completed

Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma

Lymphoma, Mixed-Cell, Follicular | Lymphoma, Small Cleaved-Cell, Follicular | Lymphoma, Low-Grade | Lymphoma, Small Lymphocytic

United States
Theravance Biopharma

Completed

Evaluate the Safety and Efficacy of a 5-HT4 Agonist in Chronic Constipation (ACCORD Trial)

Chronic Constipation

United States
Recepta Biopharma

Completed

Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

Brazil
Array BioPharma

Completed

A Safety Study of ARRY-403 in Patients With Type 2 Diabetes

Type 2 Diabetes

United States
Limerick BioPharma

Unknown

Safety, Tolerability, PK, and PD of LIM-0705 in Subjects With Impaired Glucose Tolerance or Abnormal HOMA-IR

Insulin Resistance | Impaired Glucose Tolerance

United States
Limerick BioPharma

Completed

Safety and Tolerability of LIM-0705 in Healthy Male Subjects (LIM)

Healthy

Australia
CTI BioPharma

Completed

CT-2106 for the Second Line Treatment of Ovarian Cancer

Ovarian Cancer

France, United Kingdom, Italy
Sonova AG

Completed

Investigating Hearing Aid Frequency Response Curves 2

Hearing Loss, Sensorineural | Hearing Loss, Bilateral

Canada
Sonova AG

Completed

Hearing Aid Performance Study for Different Spatial Configurations

Hearing Loss

Germany
Sonova AG

Completed

Phonak Behind-The-Ear Quality Evaluation

Hearing Loss, Sensorineural

United States
Sonova AG

Completed

Hearing Aid Transmitter Performance Study - SRF-366

Hearing Loss

Australia
Sonova AG

Completed

Evaluation of Extended Wear Technology

Hearing Loss

United States
Sonova AG

Completed

Evaluating Benefits of Hearing Aid Microphone Directionality Technologies

Hearing Loss

United States
Sonova AG

Terminated

Evaluation of the Clinical Benefit of a Transmitter for Contralateral Routing of Signals (CROS)

Hearing Loss

Switzerland
Sonova AG

Completed

Quality Control of CE-Certified Phonak Hearing Aids - 2020_43

Hearing Loss

Switzerland
Sonova AG

Completed

Benchmark Ear Impression Techniques

Ear Anatomy

Switzerland
Sonova AG

Withdrawn

Quality Control of CE-Certified Phonak Hearing Aids - 2019_23

Hearing Loss

Switzerland
Sonova AG

Completed

Assessment of Novel Sound Changing Principles in Hearing Instruments to Determine Their Application

Hearing Loss

Switzerland
Sonova AG

Completed

Quality Control of CE-Certified Phonak Hearing Aids - Sonova2018_05

Hearing Loss, Sensorineural

Switzerland
Sonova AG

Completed

Quality Control of CE-Certified Phonak Hearing Aids - 2017_27

Hearing Loss, Bilateral Sensorineural, Progressive

Switzerland
Sonova AG

Completed

Quality Control of CE-Certified Phonak Hearing Aids - 2016_06

Hearing Loss

Switzerland
Sonova AG

Completed

Real World Perspectives on Advancements in Hearing Aid Technology

Hearing Loss

United States
Sonova AG

Completed

Sound Quality Comparisons With Different Hearing Aid Couplings and Venting Systems

Hearing Loss, Sensorineural

United States
Sonova AG

Completed

Evaluation of Hearing Aid Benefit

Hearing Loss, Sensorineural

United States
Sonova AG

Completed

In Field Performance of a Hearing Aid Transducer

Hearing Loss

United States
Sonova AG

Completed

MyPhonak App Junior Pediatric Usability and Benefit Investigation

Hearing Loss

Germany
Sonova AG

Completed

PRINCE22 System Complete Performance Study

Hearing Loss, Bilateral | Hearing Loss, Unilateral

Germany
Sonova AG

Completed

Hearing Aid Signal Processing Comparative Study

Hearing Loss, Sensorineural

United States
Sonova AG

Completed

Quality Control of CE-Certified Phonak Hearing Aids - 2020_06

Hearing Loss

Switzerland

Clinical Trials Sponsored by Pronova BioPharma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Croatia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations